Brief: Medigene AG Says Planned 2018 EBITDA Loss Of EUR 21 - 23 Mln
22/03/2018 06:35
March 22 (Reuters) - Medigene AG MDG1k.DE :
* PTA-NEWS: MEDIGENE AG: MEDIGENE PUBLISHES 2017 ANNUAL
REPORT AND
ANNOUNCES START OF CLINICAL TRIAL WITH TCR IMMUNOTHERAPY MDG1011
* TOTAL REVENUES INCREASED BY 17%
* RAISED 2017 GUIDANCE MET, EBITDA LOSS LOWER THAN
FORECASTED;
LOSS REDUCED BY 2%
* STARTING PHASE I/II CLINICAL TRIAL WITH TCR IMMUNE CELL
THERAPY
MDG1011
* PATIENT RECRUITMENT COMPLETED FOR PHASE I/II STUDY WITH
DC
VACCINES
* COMPANY EXPECTS TO GENERATE TOTAL REVENUE OF BETWEEN EUR
7.5 -
9.5 M IN 2018
* PLANNED 2018 EBITDA LOSS OF EUR 21 - 23 M
Further company coverage: MDG1k.DE
((frankfurt.newsroom@thomsonreuters.com; +49 69 7565 1270;))
Recent news on Medigene AG
See all newsBrief: Medigene Files Application For The Opening Of Insolvency Proceedings
Brief: Medigene Files Patent For Unique Nk-Specific TCR Construct With European Patent Office
Brief: Medigene AG Says Co Amends Financial Guidance For 2024
Brief: Medigene AG Expands Protection Of KRAS Library With Filing Of New Patent Application
Brief: Medigene H1 Revenue EUR 4.5 Million